Toronto, Ontario – January 31, 2023) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and...
Completes clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance Optimized manufacturing processes substantially increases drug product yield To initiate ICH-compliant stability, forced degradation and drug product manufacturing in support of IND...
PharmaDrug completes all necessary research on lead DMT-analogue to support filing of provisional patent describing novel therapeutic and delivery device for treatment of glaucoma in Q4, 2022 PharmaDrug extends contract with investigators at Johns Hopkins University...
Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substance Clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled for delivery in second half of September 2022 Genvion...
Toronto, Ontario – August 3, 2022 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“Pharmadrug” or the “Company“), is pleased to announce that it has closed the previously announced (see press release dated May 31, 2022) sale of all of the issued and outstanding...
Toronto, Ontario – August 2, 2022 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances...
